MHRA Prepares For Safe Return To On-Site Inspections In UK
A Hybrid Model Of On- And Off-Site Activities Will Support A Single Inspection Cycle
Executive Summary
Four months after suspending all non-essential on-site inspections because of the COVID-19 pandemic, the UK medicines regulator is busy finalizing the practical arrangements needed to resume these safely at local sites.
You may also be interested in...
UK MHRA Explains Procedures For On-Site Inspections In COVID-19 Context
New guidance explains how UK-based sites and organizations can facilitate routine on-site good practice inspections that are due to restart next month.
UK MHRA Relies On Remote Drug GMP Inspections As COVID-19 Pandemic Grounds Inspectors
Experience from previous viral outbreaks has allowed the UK agency to move quickly; long-term focus is on hybrid inspection approach.
US FDA Announces Plans To Resume Domestic Inspections
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.